|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Lin,Jung Chin | Lin,Jung Chin | Charlene Yang | 02-2655-7918 | 4F, NO. 3-2, PARK ST., NANGANG DIST.,TAIPEI CITY, TAIWAN | 2016/09/26 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | Lumosa Therapeutics is dedicated to the development of innovative new drugs for the treatment of unmet medical needs in the fields of CNS and inflammatory diseases. The company is also actively engaged in scientific licensing and collaboration of first-in-class drug development. Lumosa has an experienced and well-integrated R&D and Business Development team; consist of professionals in chemical development, CMC, preclinical development, translational research, clinical development, regulatory affairs and project management, as well as intellectual property and business development. |
Market Information ( 2023/10/04 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
117.366 | 61.00 | 60.20 | 60.40 | -0.60 | 106 | N/A | N/A | ||||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2023/10/05) |
TPEx measures adopted (2023/10/05) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | N | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
![]() |
![]() |
![]() |